The store will not work correctly when cookies are disabled.
N-(2-morpholinopyrimidin-4-yl)-3-(p-tolyl)isoxazol-5-amine
ID: ALA5091372
PubChem CID: 156368882
Max Phase: Preclinical
Molecular Formula: C18H19N5O2
Molecular Weight: 337.38
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1
Standard InChI: InChI=1S/C18H19N5O2/c1-13-2-4-14(5-3-13)15-12-17(25-22-15)20-16-6-7-19-18(21-16)23-8-10-24-11-9-23/h2-7,12H,8-11H2,1H3,(H,19,20,21)
Standard InChI Key: NVJDZRRPCSKIFB-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 28 0 0 0 0 0 0 0 0999 V2000
8.0790 -5.0497 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1330 -4.3624 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.4944 -3.2502 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.6637 -3.2502 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.0251 -4.3624 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1547 -4.6651 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.9817 -3.8381 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6793 -2.7083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5046 -1.8845 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.6346 -2.1873 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.9380 -3.3108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1163 -4.1421 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.0677 -3.6135 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.8947 -2.7866 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0243 -3.0893 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.3270 -4.2190 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.5001 -5.0459 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3704 -4.7432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0034 -4.6651 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7003 -5.7948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5737 -6.0955 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7465 -5.2683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0455 -4.1436 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1728 -3.8346 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6168 -5.5710 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
4 5 1 0
5 1 2 0
5 6 1 0
6 7 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
12 11 2 0
7 12 1 0
13 11 1 0
13 14 1 0
15 14 1 0
16 15 1 0
17 16 1 0
18 17 1 0
13 18 1 0
19 2 1 0
20 19 2 0
21 20 1 0
22 21 2 0
23 22 1 0
24 23 2 0
19 24 1 0
22 25 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 337.38 | Molecular Weight (Monoisotopic): 337.1539 | AlogP: 3.02 | #Rotatable Bonds: 4 |
Polar Surface Area: 76.31 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.63 | CX Basic pKa: 5.70 | CX LogP: 3.65 | CX LogD: 3.62 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.78 | Np Likeness Score: -2.00 |
References
1. (2021) Isoxazole derivatives targeting tacc3 as anticancer agents, |